A Look At Glaukos (GKOS) Valuation After FDA Label Expansion For iDose TR [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
Glaukos (GKOS) is back in focus after the U.S. FDA approved a labeling update for its iDose TR glaucoma therapy, allowing repeat administration under a defined protocol backed by safety and tolerability data. See our latest analysis for Glaukos. The FDA labeling win comes after a strong 90 day share price return of 36.61% and a 30 day share price return of 7.82%. However, the 1 year total shareholder return shows a 23.69% decline, while the 3 year total shareholder return of 131.72% highlights how powerful the longer term swings have been. If this kind of progress in eye health is on your radar, it could be a good time to widen your watchlist and check out healthcare stocks So with Glaukos closing at US$119.38, trading at a discount to analyst targets and carrying a very low value score, is the recent FDA catalyst still creating a buying opportunity, or is the market already pricing in future growth? With Glaukos last closing at $119.38 and the most followed narrative point
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus CareBusiness Wire
- Should Glaukos' (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors? [Yahoo! Finance]Yahoo! Finance
- Glaukos Corporation Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $131.00 price target on the stock.MarketBeat
- Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.MarketBeat
GKOS
Earnings
- 2/17/26 - Miss
GKOS
Sec Filings
- 3/25/26 - Form 144
- 3/24/26 - Form 144
- 3/19/26 - Form 4
- GKOS's page on the SEC website